The Agency for Health Technology Assessment and Tariff System (AOTMiT) in Poland has officially recommended Kisqali (ribociclib) for inclusion in the national drug program targeting breast cancer patients. This decision marks a significant advancement in the treatment options available for individuals diagnosed with ICD-10: C50 breast cancer.
Comprehensive Evaluation Process
On May 21, 2025, AOTMiT President issued Recommendation No. 65/2025, following an extensive appraisal process. The evaluation encompassed clinical, economic, and systemic analyses to determine Kisqali’s efficacy and impact on the healthcare system. The recommendation supports Kisqali’s reimbursement under the B.9.FM drug program, ensuring accessibility for patients requiring this advanced therapy.
Stakeholder Feedback and Analysis
The appraisal process included detailed feedback from various stakeholders, including pharmaceutical companies and medical experts. Notably, Novartis Poland and Fundacja OmeaLife submitted comments addressing comparative studies and the drug’s effectiveness. AOTMiT reviewed these inputs thoroughly, maintaining its stance that Kisqali offers substantial benefits without altering the final recommendation.
- Kisqali demonstrates significant improvement in overall survival rates for breast cancer patients.
- Economic analysis confirms the drug’s cost-effectiveness within the national healthcare framework.
- Stakeholder comments were considered but did not impact the positive recommendation.
The endorsement of Kisqali by AOTMiT underscores the agency’s commitment to enhancing cancer treatment protocols. By including Kisqali in the reimbursement program, Poland ensures that patients have access to cutting-edge therapies that can improve outcomes and quality of life.
This decision not only broadens the therapeutic arsenal against breast cancer but also reflects the thorough and unbiased assessment methodologies employed by AOTMiT. Patients and healthcare providers can now benefit from Kisqali’s proven efficacy, reinforcing Poland’s dedication to advancing medical treatments and supporting those battling breast cancer.
This article has been prepared with the assistance of AI and reviewed by an editor. For more details, please refer to our Terms and Conditions. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author.
